Asset Details
Do you wish to reserve the book?
B-Lymphoblastic Leukemia With Aberrant CD5 Expression: Clinicopathologic Features and Outcome in 10 Cases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
B-Lymphoblastic Leukemia With Aberrant CD5 Expression: Clinicopathologic Features and Outcome in 10 Cases
Do you wish to request the book?
B-Lymphoblastic Leukemia With Aberrant CD5 Expression: Clinicopathologic Features and Outcome in 10 Cases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
B-Lymphoblastic Leukemia With Aberrant CD5 Expression: Clinicopathologic Features and Outcome in 10 Cases
2021
Overview
Objectives: B-acute lymphoblastic leukemia (B-ALL) is a neoplasm of precursor lymphoid cells committed to the B-lineage. Expression of CD5 is rare in B-ALL. Methods: We studied the clinicopathologic, immunophenotypic, and molecular genetic features of 10 cases of B-ALL with aberrant CD5 expression, and compared with CD5- B-ALL. Results: B-ALL with aberrant CD5 expression is rare and predominantly affects men. Patients with CD5+ B-ALL had shorter median overall survival (21 vs 45 months, P = .0003). Expression of CD5 imposed a challenge in the differential diagnoses between B-ALL and other CD5+ B-cell lymphomas with blastic morphology. Dim CD20 and CD45, lack of surface immunoglobulin, expression of CD34 and TdT, negative immunostain for cyclin D1, and absence of t(11;14)(q13;q32) support a diagnosis of B-ALL. Conclusions: CD5 expression is rare in B-ALL and associated with poor clinical outcome. CD5+ B-ALL represents a distinct entity that needs to be considered in the differential diagnoses of CD5+ B-cell lymphoproliferative disorders.
Publisher
Oxford University Press
Subject
